Table 1 Baseline characteristics* for the entire study cohort and by vertebral fracture status
| Â | Â | Overall n = 49 | Nonfracture Group n = 41 | Fracture Groupa n = 8 | p-value |
|---|---|---|---|---|---|
| Â | Valid n, Nonfracture/Fracture | Â | Â | Â | Â |
Male gender, % | 41/8 | 42.9 | 39.0 | 62.5 | 0.263 |
Age, years | 41/8 | 25.2 (9.4) | 23.8 (8.7) | 32.7 (10.3) | 0.024†|
Weight, kg | Â | Â | Â | Â | Â |
   males | 16/5 | 59.5 (9.2) | 56.1 (7.4) | 70.4 (5.3) | 0.003†|
   females | 25/3 | 57.4 (16.4) | 57.3 (17.5) | 58.0 (11.5) | 0.726 |
Height, cm, | 41/8 | 166.8 (7.9) | 166.1 (7.7) | 170.3 (8.9) | 0.175 |
BMI, kg/m2 | Â | Â | Â | Â | Â |
   males | 16/5 | 19.8 (2.8) | 18.9 (2.2) | 22.8 (2.4) | 0.004†|
   females | 25/3 | 21.7 (5.1) | 21.7 (5.3) | 22.3 (3.7) | 0.726 |
FEV1 | 39/8 | 2.2 (0.9) | 2.2 (0.9) | 2.5 (0.7) | 0.202 |
FVC | 39/8 | 3.1 (0.9) | 3.0 (0.9) | 3.4 (0.9) | 0.098 |
Hemoglobin g/L | 38/7 | 139.2 (14.8) | 138.1 (14.6) | 144.9 (15.2) | 0.301 |
Creatinine, umol/L | 34/7 | 66.8 (17.4) | 64.8 (18.1) | 76.0 (10.0) | 0.045†|
Calcium, mmol/L | 34/5 | 2.3 (0.1) | 2.3 (0.1) | 2.3 (0.1) | 0.657 |
Albumin, g/L | 37/8 | 39.7 (3.7) | 39.8 (3.9) | 39.3 (2.5) | 0.550 |
25-hydroxyvitamin D, nmol/L | 26/4 | 61.9 (28.8) | 61.5 (31.0) | 64.6 (5.4) | 0.617 |
Parathyroid hormone, pg/ml | 17/4 | 28.0 (17.7) | 24.8 (18.0) | 41.5 (6.7) | 0.120 |
Phosphate, mmol/L | 32/5 | 1.2 (0.2) | 1.2 (0.2) | 1.3 (0.1) | 0.813 |
Alkaline Phosphatase, U/L | 37/8 | 121.8 (91.4) | 116.6 (89.7) | 146.1 (101.5) | 0.082 |
Alanine Aminotransferase, IU/L | 36/8 | 32.5 (29.1) | 29.6 (22.0) | 45.6 (50.5) | 0.560 |
g-glutamyltransferase, U/L | 37/7 | 31.2 (51.8) | 26.7 (39.9) | 55.1 (94.2) | 0.297 |
Inhaled Steroids, % yes | 41/8 | 55.1 | 51.2 | 75.0 | 0.269 |
Vitamin D (ADEK), % yes | 41/8 | 55.1 | 53.7 | 62.5a | 0.715 |